Andrea M Griesinger, Annaliese J Calzadilla, Enrique Grimaldo, Andrew M Donson, Vladimir Amani, Angela M Pierce, Jenna Steiner, Soudabeh Kargar, Natalie J Serkova, Kelsey C Bertrand, Karen D Wright, Rajeev Vibhakar, Todd Hankinson, Michael Handler, Holly B Lindsay, Nicholas K Foreman, Kathleen Dorris
PURPOSE: There are no effective treatment strategies for children with highest-risk posterior fossa ependymoma (PFA). Chromosome 1q gains (1q+) are present in approximately 25% of newly diagnosed PFA tumors and this number doubles at recurrence. Seventy percent of children with chromosome 1q+ PFA will die because of the tumor, highlighting the urgent need to develop new therapeutic strategies for this population. EXPERIMENTAL DESIGN: In this study we utilize 1q+ PFA in vitro and in vivo models to test the efficacy of combination radiation and chemotherapy in a preclinical setting...
February 9, 2024: Clinical Cancer Research